2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Nicolaus Kröger, MD, discusses the long-term results of a phase 2 study in multiple myeloma.
Nicolaus Kröger, MD, professor, medical director, Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany, discusses the long-term results of a phase 2 study in multiple myeloma.
During the 47th Annual Meeting of the EBMT, updated results of a prospective, phase 2 study (NCT00777998) comparing tandem stem cell transplantation approaches plus maintenance thalidomide (Thalomid) in patients with multiple myeloma were presented virtually. The study evaluated 210 patients up to the age of 60 with multiple myeloma who underwent autologous stem cell transplant and allogeneic stem cell transplant (auto-allo) or autologous tandem transplant (auto-auto). Both regimens were followed by maintenance thalidomide.
The 8-year progression-free survival (PFS) rate was 43% for auto-allo vs 21% for auto-auto. The 8-year overall survival rates were 55% and 50%, respectively. However, these findings were not statistically significant because fewer patients underwent auto-allo vs auto-auto, concludes Kröger.